Juno Therapeutics (JUNO) : 8 analysts are covering Juno Therapeutics (JUNO) and their average rating on the stock is 1.38, which is read as a Strong Buy. 6 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Juno Therapeutics (JUNO) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Juno Therapeutics (JUNO) : The consensus price target for Juno Therapeutics (JUNO) is $61.13 for the short term with a standard deviation of $11.52. The most optimist securities analyst among the 8 who monitor the stock believes that the stock can reach $80, however, the pessimist price target for the company is $50.
Juno Therapeutics (NASDAQ:JUNO): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $38.81 and $38.58 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $39.95. The buying momentum continued till the end and the stock did not give up its gains. It closed at $39.94, notching a gain of 0.88% for the day. The total traded volume was 931,542 . The stock had closed at $39.59 on the previous day.
Also, Raymond James initiates coverage on Juno Therapeutics (NASDAQ:JUNO). According to the latest information available, the shares are now rated Outperform by the analysts at the agency. The rating by the firm was issued on June 2, 2016. The company shares have dropped -19.37% from its 1 Year high price. On Dec 1, 2015, the shares registered one year high at $57.82 and the one year low was seen on Feb 3, 2016. The 50-Day Moving Average price is $42.02 and the 200 Day Moving Average price is recorded at $38.66.
Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.